{"id":"atrasentan-low-dose-group","safety":{"commonSideEffects":[{"rate":"10%","effect":"Edema"},{"rate":"8%","effect":"Fatigue"},{"rate":"6%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Atrasentan works by selectively blocking the endothelin receptor, which is involved in the regulation of blood pressure and vascular tone.","oneSentence":"Endothelin receptor antagonist","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:34.394Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pulmonary arterial hypertension"}]},"trialDetails":[{"nctId":"NCT01424319","phase":"PHASE2","title":"Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-08","conditions":"Chronic Kidney Disease, Diabetic Nephropathy","enrollment":58},{"nctId":"NCT01399580","phase":"PHASE2","title":"A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-08","conditions":"Chronic Kidney Disease, Diabetic Nephropathy","enrollment":48},{"nctId":"NCT01356849","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2011-04","conditions":"Chronic Kidney Disease, Diabetic Nephropathy","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Atrasentan low dose group","genericName":"Atrasentan low dose group","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endothelin receptor antagonist Used for Pulmonary arterial hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}